申请人:Hayashibe Satoshi
公开号:US20090186916A1
公开(公告)日:2009-07-23
Provided is a compound that is an NMDA receptor antagonist having a broader safety margin, and is useful as an agent for treating or preventing Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, or pain.
A novel compound or a salt thereof, which is characterized in that it has an amino group and R
1
(lower alkyl, cycloalkyl, -lower alkylene-aryl, aryl which may be substituted, and the like) on carbon atoms of indane, cyclopenta[b]thiophene, cyclopenta[b]furan, cyclopenta[b]pyridine, or cyclopenta[c]pyridine ring, or 2,3-dihydrdo-1-benzofuran, 2,3-dihydrdo-1-benzothiophene, indoline ring, or the like, and has R
2
and R
3
(the same or different, each lower alkyl or aryl) on carbon atoms beside them, and an NMDA receptor antagonist comprising the same as an active component.
提供的化合物是一种NMDA受体拮抗剂,具有更广泛的安全边际,可用作治疗或预防阿尔茨海默病、脑血管性痴呆、帕金森病、缺血性卒中或疼痛的药剂。
一种新型化合物或其盐,其特征在于在茚烷、环戊[b]噻吩、环戊[b]呋喃、环戊[b]吡啶或环戊[c]吡啶环的碳原子上具有氨基和R1(较低的烷基、环烷基、-较低的烷基-芳基、可能被取代的芳基等),或2,3-二氢-1-苯并呋喃、2,3-二氢-1-苯并噻吩、吲哚环或类似物,并且在它们旁边的碳原子上具有R2和R3(相同或不同,每个都是较低的烷基或芳基),以及包含其作为活性成分的NMDA受体拮抗剂。